Issue 42 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Lomustine's path from unavailable but cheap to plentiful but expensive

Purdue's Thompson: Lomustine establishes proof of principle for resolving cancer drug shortages

Texas votes to keep CPRIT open with another $3 billion in state funding

Sharpless returns to NCI; Hahn to be nominated FDA commissioner; Giroir assumes acting role

FDA Office of Hematology and Oncology Products is now Office of Oncologic Diseases

Major gaps persist in Americans' knowledge of and actions on cancer prevention

In Brief

Carolyn Hayes named nursing leader at Rutgers Cancer Institute and RWJBarnabas Health

Elaine Fuchs receives Ohio State's Block Memorial Lectureship Award

ACCC recognizes seven cancers programs with Innovator Awards at 36th National Oncology Conference

Brawley receives University of Chicago Professional Achievement Award

ASCO, IASLC work to improve lung cancer care in Brazil

NIH REACH awards five new Hubs $4M each

Clinical Roundup

Phase III trial of Ninlaro as first-line maintenance therapy meets PFS in multiple myeloma

Inovio demonstrates 80% 6-month PFS in phase II glioblastoma multiforme study with INO-5401 + Libtayo

AppliedVR and NCI evaluate virtual reality to address cancer-related anxiety

Thermo Fisher Scientific introduces NGS platform that delivers faster results

NCI Trials

NCI Trials for November 2019

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login